Robert W. Baird Issues Positive Forecast for Caris Life Sciences (NASDAQ:CAI) Stock Price

Caris Life Sciences (NASDAQ:CAI) had its target price hoisted by Robert W. Baird from $26.00 to $28.00 in a research report report published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Evercore set a $38.00 price target on shares of Caris Life Sciences in a report on Monday, January 5th. Canaccord Genuity Group raised their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Finally, Wall Street Zen lowered Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $33.50.

Caris Life Sciences Trading Up 4.7%

Shares of NASDAQ:CAI traded up $0.90 during trading on Friday, reaching $20.14. The company’s stock had a trading volume of 4,834,513 shares, compared to its average volume of 2,242,218. The company’s 50 day moving average price is $24.42. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79. Caris Life Sciences has a 12 month low of $17.15 and a 12 month high of $42.50. The stock has a market cap of $5.68 billion and a PE ratio of -43.78.

Caris Life Sciences (NASDAQ:CAI) last announced its earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analysts’ expectations of $281.00 million. During the same quarter last year, the firm posted ($1.73) EPS. Caris Life Sciences’s revenue for the quarter was up 125.4% compared to the same quarter last year.

Insider Buying and Selling at Caris Life Sciences

In related news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total value of $1,654,605.00. Following the completion of the sale, the insider owned 99,571 shares in the company, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Caris Life Sciences

Several institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. lifted its stake in Caris Life Sciences by 14.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after acquiring an additional 1,180,200 shares during the period. Braidwell LP lifted its position in shares of Caris Life Sciences by 6.8% in the 4th quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock worth $210,880,000 after purchasing an additional 500,000 shares during the period. PointState Capital LP boosted its stake in shares of Caris Life Sciences by 73.0% during the fourth quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after purchasing an additional 2,834,986 shares in the last quarter. Orbimed Advisors LLC increased its holdings in Caris Life Sciences by 2.7% during the fourth quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock valued at $84,070,000 after buying an additional 81,153 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Caris Life Sciences by 185.0% in the fourth quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock worth $65,974,000 after buying an additional 1,587,176 shares in the last quarter.

Key Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.